CD274 and non-small cell lung carcinoma: While programmed death ligand-1 (PD-L1) expression has served as a standard biomarker for predicting responses to anti-PD-1 or anti-PD-L1 therapies in NSCLC, ongoing research is delving into emerging predictive biomarkers.